Bio-Rad Adds Rapid Bispecific Antibody Prototyping and Screening Services To Pioneer Antibody Discovery Platform

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the expansion of its Pioneer™ Antibody Discovery Platform services with the addition of fast generation and screening of bispecific antibodies, based on the company’s proprietary SpyLock Technology.

The SpyLock service builds upon the capabilities of the Pioneer Platform, enabling customers to rapidly generate and screen bispecific antibodies to identify effective antibody combinations to take forward into development. The Pioneer Platform comprises a fully human synthetic phage display library of 225 billion unique Fab antibodies, and its proprietary SpyDisplay technology enables the rapid delivery of high-quality antibody candidates. The platform is paired with a high quality and comprehensive suite of discovery services that can be customized to meet the needs of any project.

The Pioneer Platform is being harnessed by organizations globally, across applications including immuno-oncology and infectious diseases. Bio-Rad’s Pioneer partnerships include a successful collaboration with Salipro Biotech (https://salipro.com/) for the identification of high-quality antibody leads against challenging GPCR targets. The collaboration has already successfully generated multiple novel human antibodies against one of the targets with affinities exceeding the existing first-in-class antibody. The new antibodies exhibited promising functional activity and offer the potential for enhanced efficacy and novel immuno-oncology therapeutic avenues.

“Progress in the development of various platforms for generating bispecific antibodies has led to an increase in these clinically superior therapeutics passing through clinical trials and achieving market approvals. The addition of SpyLock as part of our Pioneer Platform provides a cutting-edge solution to support the screening of bispecific antibodies,” said John Cardone, Marketing Manager, Custom Antibodies, Life Science Group, Bio-Rad. “The continued expansion of our antibody services reflects our commitment to creating novel support options for our customers, enabling researchers to screen therapeutic bispecific antibody candidates in industry-leading timelines.”